Why and how increased plasma ceramides predict future cardiovascular events?

Atherosclerosis. 2020 Dec:314:71-73. doi: 10.1016/j.atherosclerosis.2020.09.030. Epub 2020 Oct 9.

Authors

Katariina Öörni¹, Matti Jauhiainen², Petri T Kovanen³

Affiliations

¹ Atherosclerosis Research Laboratory, Wihuri Research Institute, Helsinki, Finland; Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland. Electronic address: kati.oorni@wri.fi.
² Minerva Foundation Institute for Medical Research, Helsinki, Finland.
³ Atherosclerosis Research Laboratory, Wihuri Research Institute, Helsinki, Finland.

PMID: 33121744
DOI: 10.1016/j.atherosclerosis.2020.09.030

No abstract available

Keywords: Biomarker; Ceramide; Lipoprotein; Sphingomyelinase.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Ceramides*
Coronary Artery Disease*
Humans
Plasma
Sphingomyelin Phosphodiesterase

Substances

Ceramides
Sphingomyelin Phosphodiesterase